Eileen E Birch1, Reed M Jost2, Angie De La Cruz2, Krista R Kelly2, Cynthia L Beauchamp3, Lori Dao3, David Stager4, Joel N Leffler5. 1. Retina Foundation of the Southwest, Dallas, Texas; UT Southwestern Medical Center, Dallas, Texas. Electronic address: ebirch@rfsw.org. 2. Retina Foundation of the Southwest, Dallas, Texas. 3. ABC Eyes, Dallas, Texas. 4. Pediatric Ophthalmology & Adult Strabismus, Plano, Texas. 5. Children's Eye Care of North Texas, Plano, Texas.
Abstract
BACKGROUND: Binocular amblyopia treatments promote visual acuity recovery and binocularity by rebalancing the signal strength of dichoptic images. Most require active participation by the amblyopic child to play a game or perform a repetitive visual task. The purpose of this study was to investigate a passive form of binocular treatment with contrast-rebalanced dichoptic movies. METHODS: A total of 27 amblyopic children, 4-10 years of age, wore polarized glasses to watch 6 contrast-rebalanced dichoptic movies on a passive 3D display during a 2-week period. Amblyopic eye contrast was 100%; fellow eye contrast was initially set to a lower level (20%-60%), which allowed the child to overcome suppression and use binocular vision. Fellow eye contrast was incremented by 10% for each subsequent movie. Best-corrected visual acuity, random dot stereoacuity, and interocular suppression were measured at baseline and at 2 weeks. RESULTS: Amblyopic eye best-corrected visual acuity improved from 0.57 ± 0.22 at baseline to 0.42 ± 0.23 logMAR (t26 = 8.09; P < 0.0001; 95% CI for improvement, 0.11-0.19 logMAR). Children aged 3-6 years had more improvement (0.21 ± 0.11 logMAR) than children aged 7-10 years (0.11 ± 0.06 logMAR; t25 = 3.05; P = 0.005). Children with severe amblyopia (≥0.7 logMAR) at baseline experienced greater improvement (0.24 ± 0.12 logMAR) than children with moderate amblyopia at baseline (0.12 ± 0.06 logMAR; t25 = 3.49; P = 0.002). CONCLUSIONS: In this cohort, passive viewing of contrast-rebalanced dichoptic movies effectively improved visual acuity in amblyopic subjects. The degree of improvement observed was similar to that previously reported for 2 weeks of binocular games treatment and with 3-4 months of occlusion therapy.
BACKGROUND:Binocular amblyopia treatments promote visual acuity recovery and binocularity by rebalancing the signal strength of dichoptic images. Most require active participation by the amblyopic child to play a game or perform a repetitive visual task. The purpose of this study was to investigate a passive form of binocular treatment with contrast-rebalanced dichoptic movies. METHODS: A total of 27 amblyopic children, 4-10 years of age, wore polarized glasses to watch 6 contrast-rebalanced dichoptic movies on a passive 3D display during a 2-week period. Amblyopic eye contrast was 100%; fellow eye contrast was initially set to a lower level (20%-60%), which allowed the child to overcome suppression and use binocular vision. Fellow eye contrast was incremented by 10% for each subsequent movie. Best-corrected visual acuity, random dot stereoacuity, and interocular suppression were measured at baseline and at 2 weeks. RESULTS: Amblyopic eye best-corrected visual acuity improved from 0.57 ± 0.22 at baseline to 0.42 ± 0.23 logMAR (t26 = 8.09; P < 0.0001; 95% CI for improvement, 0.11-0.19 logMAR). Children aged 3-6 years had more improvement (0.21 ± 0.11 logMAR) than children aged 7-10 years (0.11 ± 0.06 logMAR; t25 = 3.05; P = 0.005). Children with severe amblyopia (≥0.7 logMAR) at baseline experienced greater improvement (0.24 ± 0.12 logMAR) than children with moderate amblyopia at baseline (0.12 ± 0.06 logMAR; t25 = 3.49; P = 0.002). CONCLUSIONS: In this cohort, passive viewing of contrast-rebalanced dichoptic movies effectively improved visual acuity in amblyopic subjects. The degree of improvement observed was similar to that previously reported for 2 weeks of binocular games treatment and with 3-4 months of occlusion therapy.
Authors: P S Moke; A H Turpin; R W Beck; J M Holmes; M X Repka; E E Birch; R W Hertle; R T Kraker; J M Miller; C A Johnson Journal: Am J Ophthalmol Date: 2001-12 Impact factor: 5.258
Authors: David K Wallace; Allison R Edwards; Susan A Cotter; Roy W Beck; Robert W Arnold; William F Astle; Carmen N Barnhardt; Eileen E Birch; Sean P Donahue; Donald F Everett; Joost Felius; Jonathan M Holmes; Raymond T Kraker; Michele Melia; Michael X Repka; Nicholas A Sala; David I Silbert; Katherine K Weise Journal: Ophthalmology Date: 2006-06 Impact factor: 12.079
Authors: Michael X Repka; David K Wallace; Roy W Beck; Raymond T Kraker; Eileen E Birch; Susan A Cotter; Sean Donahue; Donald F Everett; Richard W Hertle; Jonathan M Holmes; Graham E Quinn; Mitchell M Scheiman; David R Weakley Journal: Arch Ophthalmol Date: 2005-02
Authors: Susan A Cotter; Raymond H Chu; Danielle L Chandler; Roy W Beck; Jonathan M Holmes; Melissa L Rice; Richard W Hertle; Eileen E Birch; Pamela S Moke Journal: Am J Ophthalmol Date: 2003-10 Impact factor: 5.258
Authors: Michael X Repka; Roy W Beck; Jonathan M Holmes; Eileen E Birch; Danielle L Chandler; Susan A Cotter; Richard W Hertle; Raymond T Kraker; Pamela S Moke; Graham E Quinn; Mitchell M Scheiman Journal: Arch Ophthalmol Date: 2003-05
Authors: Catherine E Stewart; Merrick J Moseley; David A Stephens; Alistair R Fielder Journal: Invest Ophthalmol Vis Sci Date: 2004-09 Impact factor: 4.799
Authors: Reed M Jost; Krista R Kelly; Jeffrey S Hunter; David R Stager; Becky Luu; Joel N Leffler; Lori Dao; Cynthia L Beauchamp; Eileen E Birch Journal: J AAPOS Date: 2020-10-09 Impact factor: 1.220
Authors: Reed M Jost; Lindsey A Hudgins; Lori M Dao; David R Stager; Becky Luu; Cynthia L Beauchamp; Jeffrey S Hunter; Prashanthi Giridhar; Yi-Zhong Wang; Eileen E Birch Journal: Sci Rep Date: 2022-03-09 Impact factor: 4.379
Authors: Eileen E Birch; Reed M Jost; Yi-Zhong Wang; Krista R Kelly; Deborah E Giaschi Journal: Invest Ophthalmol Vis Sci Date: 2019-08-01 Impact factor: 4.799
Authors: Mirella Telles Salgueiro Barboni; Otto Alexander Maneschg; János Németh; Zoltán Zsolt Nagy; Zoltán Vidnyánszky; Éva M Bankó Journal: Invest Ophthalmol Vis Sci Date: 2020-09-01 Impact factor: 4.799